Home
Contact Us Site Map Search
Reproductive Health Technologies Project  
Abortion Contraception STDs Fertility Integrity of Science News & Publications About Us
  Print this page  
 
Mifepristone
 
 

In September 2000, the United States Food and Drug Administration (FDA) approved mifepristone (brand name, Mifeprex) for early pregnancy termination. Because early medical options like mifepristone can be offered safely in a variety of settings, they offer women a greater degree of privacy and control over the process of terminating an unwanted pregnancy.

Frequently Asked Questions about Mifepristone

How does mifepristone work?

How does a woman take mifepristone to terminate a pregnancy?

Why do some healthcare providers offer mifepristone medical abortion in a different regimen than recommended by the FDA?

What are the benefits to using mifepristone?

What are the side effects?

Who should not use mifepristone?

Who can offer Mifeprex?

Will insurance cover the use of Mifeprex?

How does Mifeprex differ from emergency contraception or the "morning after pill"?

Don't see your question here? Let us know.

How does mifepristone work?
Mifepristone terminates a pregnancy by blocking the receptors of the hormone progesterone, which is needed for a pregnancy to continue. It also increases prostaglandin levels and dilates the cervix, facilitating abortion. When followed by administration of misoprostol, a prostaglandin that induces uterine contractions, mifepristone ends an unwanted pregnancy approximately 94–98% of the time.

back to top

How does a woman take mifepristone to terminate a pregnancy?
Under the FDA approved regimen for Mifeprex (mifepristone), a woman first takes 600 mg of mifepristone (three 200-mg pills by mouth). Two days later, she takes 400 micrograms (two 200 microgram pills) of misoprostol. Approximately 14 days after taking the mifepristone, she returns to the healthcare provider for a follow-up visit approximately to determine whether the pregnancy has been terminated.

back to top

Why do some healthcare providers offer mifepristone medical abortion in a different regimen than recommended by the FDA?
Research and real world experience with mifepristone has shown that alternatives to the FDA-approved regimen are safe, effective, and in most cases, preferable to the FDA regimen. For example, studies indicate that a 200 mg dose of mifepristone is as effective as the 600 mg FDA-approved dosage. A recent study also found that administering misoprostol either one or three days after mifepristone was as effective as the FDA-mandated two-day period. Other acceptable alternatives include extending the use of mifepristone under the approved regimen up to 56 days gestation or offering 200 mg mifepristone with 800 micrograms of misoprostol vaginally to extend the use of medical abortion up to 63 days gestation. Additionally, extensive clinical data support the safety and efficacy of administration of misoprostol at home.

back to top

What are the benefits to using mifepristone to terminate a pregnancy?
Abortion using mifepristone has several advantages over surgical abortion. Mifepristone carries no risk of uterine perforation or rare complications caused by anesthesia and lower risk of infection. Many women feel that medical abortion is noninvasive, more natural, and more private than surgical abortion. 1 When given a choice between medical and surgical abortion, 57–70 % of women choose the medical option. 2 96% of women in clinical trials of mifepristone said they would recommend this method to a friend. 3

back to top

What are the side effects of mifepristone?
All women who use mifepristone experience bleeding and cramping; both symptoms are normal and part of the medical abortion process. Other side effects include nausea, headache, vomiting, diarrhea, dizziness, back pain and tiredness. These side effects tend to lessen after the third day after taking mifepristone and are usually gone within two weeks. Serious adverse events, like hospitalization or blood transfusions, are extremely rare.

back to top

Who should not use mifepristone?
Mifepristone is not appropriate for women who have:

  • Ectopic pregnancies
  • Intrauterine device in place
  • Chronic failure of the adrenal glands
  • Porphyria
  • Current long-term therapy with corticosteroids
  • History of allergy to mifepristone or other prostaglandins
  • Bleeding disorders or are undergoing blood-thinning therapy

back to top

Who can offer mifepristone medical abortion in the United States?
Mifeprex (mifepristone) is only available to qualified physicians who establish an account with Danco Laboratories, the manufacturer of the drug (www.earlyoptionpill.com). Physicians who prescribe Mifeprex must be able to assess the duration of the pregnancy accurately, diagnose ectopic pregnancies, and provide surgical intervention in cases of incomplete abortion or severe bleeding — or have made plans to provide such care at other medical facilities.

back to top

Will insurance cover the use of mifepristone for medical abortion?
Many of the nation's largest health insurers routinely cover Mifeprex, in the way other drugs or surgical abortions are already reimbursed. Mifeprex will also likely be covered by those states which currently cover abortion services.

back to top

How does mifepristone differ from emergency contraception or the "morning after pill"?
Emergency contraceptive pills (ECPs) are the most common method of preventing pregnancy after unprotected sexual intercourse. The use of emergency contraceptive pills does not cause an abortion. If a woman wants to prevent pregnancy after sex, she can use emergency contraceptive pills. If a woman wants to terminate an unwanted pregnancy at an early stage, she can use mifepristone.

back to top


1 Population Council. Mifepristone, At Last. Momentum. (Jan 2001). http://www.popcouncil.org/publications/momentum/momentum1200_1.html

2 Jones R, Henshaw, S. Mifepristone for Early Medical Abortion: Experiences in France , Great Britain and Sweden . Perspectives on Sexual and Reproductive Health (May/June 2002), citing Cameron et al., Impact of the Introduction of New Medical Methods on Therapeutic Abortions at the Royal Infirmary in Edinburgh , British J. of Obstetrics & Gynaecology, 1996 103(12): 1222-1229 and Winikoff B., Acceptability of Medical Abortion in Early Pregnancy, 1995 Family Planning Perspectives 142 -48, 185 (1995).

3 Winikoff, B, et al., Acceptability and Feasibility of Early Pregnancy Termination by Mifepristone-Misoprostol, 7 Archives of Family Medicine 360 (July/Aug. 1998).

back to top

 
Resources
January 30th New York Times article on Mifepristone
Dr. Wood Testifies at House Hearing on RU-486
[PDF, 27KB]
RHTP and Coalition Partners Comment on Medical Abortion Safety to CDC on May 11
[PDF, 257KB

April 10th UPDATE - Frequently Asked Questions about Fatal Infection and Mifepristone Medical Abortion [PDF, 151KB]

Medication Abortion website
This site is designed to provide accurate information about medication abortion to health service providers including physicians, nurse practitioners, physician assistants, counselors, and office staff.
Medical Abortion Education Project
The Medical Abortion Education Project (MAEP) was designed to to meet the challenge of ensuring the availability of medical abortions by increasing the number of healthcare providers who advocate medical abortion training and service delivery within their communities.
Danco Laboratories
Manufacturer of Mifeprex (mifepristone)
 
 
Abortion | Contraception | STDs | Fertility | Integrity of Science | News & Publications | About Us
Contact Us | Site Map